Health Care [ 12/12 ] | Life Sciences Tools & Services [ 71/74 ]
NASDAQ | Common Stock
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally.
The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.
This segment also provides testing and laboratory services to the dental and pharmaceutical industries.
The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research.
The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides.
The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments.
This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands.
The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 5, 24 | 0.84 Increased by +940.00% | 0.44 Increased by +90.91% |
| May 31, 24 | 3.70 Increased by +3.26 K% | -0.11 Increased by +3.46 K% |
| Feb 5, 24 | 0.39 Increased by +387.50% | 0.19 Increased by +105.26% |
| Nov 6, 23 | -0.23 Decreased by -195.83% | 0.16 Decreased by -243.75% |
| Aug 3, 23 | -0.10 Increased by +62.96% | -0.02 Decreased by -400.00% |
| May 25, 23 | 0.11 Increased by +132.35% | 0.37 Decreased by -70.27% |
| Feb 6, 23 | 0.08 Decreased by -86.89% | 0.14 Decreased by -42.86% |
| Nov 3, 22 | 0.24 Decreased by -65.71% | -0.31 Increased by +177.42% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 57.83 M Increased by +8.78% | 3.43 M Increased by +378.70% | Increased by +5.93% Increased by +356.20% |
| Jun 30, 24 | 58.17 M Increased by +14.86% | 3.39 M Increased by +717.12% | Increased by +5.82% Increased by +637.29% |
| Mar 31, 24 | 58.90 M Increased by +5.96% | -254.58 M Decreased by -41.77 K% | Decreased by -432.20% Decreased by -39.42 K% |
| Dec 31, 23 | 53.47 M Decreased by -1.50% | 2.12 M Increased by +369.18% | Increased by +3.96% Increased by +376.32% |
| Sep 30, 23 | 53.16 M Decreased by -9.50% | -1.23 M Decreased by -194.18% | Decreased by -2.31% Decreased by -204.07% |
| Jun 30, 23 | 50.65 M Increased by +0.38% | -549.00 K Increased by +61.82% | Decreased by -1.08% Increased by +61.97% |
| Mar 31, 23 | 55.59 M Decreased by -5.58% | 611.00 K Increased by +134.25% | Increased by +1.10% Increased by +136.27% |
| Dec 31, 22 | 54.29 M Decreased by -0.75% | 451.00 K Increased by +121.89% | Increased by +0.83% Increased by +122.06% |